

Laboratory markers in IBD: useful, magic, or unnecessary

Gut

55, 426-431

DOI: [10.1136/gut.2005.069476](https://doi.org/10.1136/gut.2005.069476)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Evolving diagnostic strategies for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2006, 8, 478-485.	1.1	19
2	Correlated Expression of High-Sensitivity C-Reactive Protein in Relation to Disease Activity in Inflammatory Bowel Disease: Lack of Differences between Crohn's Disease and Ulcerative Colitis. <i>Digestion</i> , 2006, 73, 205-209.	1.2	34
3	Laboratory Values for Children With Newly Diagnosed Inflammatory Bowel Disease. <i>Pediatrics</i> , 2007, 119, 1113-1119.	1.0	149
4	Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1051-1059.	1.4	41
5	Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. <i>Gut</i> , 2007, 56, 1706-1713.	6.1	177
6	Use of Serologic Markers as a Screening Tool in Inflammatory Bowel Disease Compared With Elevated Erythrocyte Sedimentation Rate and Anemia. <i>Pediatrics</i> , 2007, 119, e193-e199.	1.0	41
7	The Certain Uncertainty of Measuring Disease Activity in IBD. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 123-125.	1.1	5
8	Enzymes in feces: Useful markers of chronic inflammatory bowel disease. <i>Clinica Chimica Acta</i> , 2007, 381, 63-68.	0.5	100
9	Inflammatory Bowel Disease in the Pediatric Patient. <i>Surgical Clinics of North America</i> , 2007, 87, 643-658.	0.5	15
11	Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. <i>Digestive and Liver Disease</i> , 2007, 39, 422-429.	0.4	19
12	Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. <i>Digestive and Liver Disease</i> , 2007, 39, 1006-1010.	0.4	38
13	Diagnostic utility of serology: If the glove does not fit, you need not submit. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1448-1449.	0.9	0
14	Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barré syndrome revealed by proteomics analysis. <i>Proteomics - Clinical Applications</i> , 2007, 1, 467-475.	0.8	25
15	Evaluation of disease activity markers in dogs with idiopathic inflammatory bowel disease. <i>Journal of Small Animal Practice</i> , 2007, 48, 620-625.	0.5	55
16	Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. <i>Biochemical Pharmacology</i> , 2007, 73, 1422-1433.	2.0	104
17	CRP Correlates with Clinical Score in Ulcerative Colitis but Not in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2063-2068.	1.1	63
18	Fecal Lactoferrin and Calprotectin After Ileocolonic Resection for Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 861-869.	0.7	86
19	Accuracy of Four Fecal Assays in the Diagnosis of Colitis. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1697-1706.	0.7	79

#	ARTICLE	IF	CITATIONS
20	Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. <i>Journal of Gastroenterology</i> , 2007, 42, 754-760.	2.3	28
21	B1a lymphocytes in ulcerative colitis. <i>International Journal of Colorectal Disease</i> , 2007, 22, 1005-1011.	1.0	11
22	C-reactive protein as early predictor for infectious postoperative complications in rectal surgery. <i>International Journal of Colorectal Disease</i> , 2007, 22, 1499-1507.	1.0	169
23	Current and future diagnostic approaches: From serologies to imaging. <i>Current Gastroenterology Reports</i> , 2007, 9, 489-496.	1.1	15
24	Increased Expression of Long Pentraxin PTX3 in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1910-1916.	1.1	32
25	Fecal Calprotectin Levels in Patients with Colonic Polyposis. <i>Digestive Diseases and Sciences</i> , 2008, 53, 47-51.	1.1	29
26	Role of Procalcitonin in Infectious Gastroenteritis and Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2960-2968.	1.1	28
27	Moyens d'évaluation de l'activité au cours de la maladie de Crohn : acquis et perspectives. <i>Journal Africain D'Hepato-Gastroenterologie</i> , 2008, 2, 13-17.	0.0	0
28	Infliximab in Ulcerative Colitis is Associated with an Increased Risk of Postoperative Complications After Restorative Proctocolectomy. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 1202-1210.	0.7	263
29	Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. <i>International Journal of Colorectal Disease</i> , 2008, 23, 985-992.	1.0	71
30	Prevalence of and risk factors for vitamin B12 deficiency in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 217-223.	0.9	54
31	Enhanced formation of advanced oxidation protein products in IBD. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 794-802.	0.9	56
32	Urinary leukotriene E4 excretion: A biomarker of inflammatory bowel disease activity. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 769-774.	0.9	38
33	Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1555-1561.	0.9	65
34	Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. <i>British Journal of Pharmacology</i> , 2008, 155, 1085-1092.	2.7	61
35	Comparative analysis of Bayer wide-range C-reactive protein (wCRP) and the DadeBehring high sensitivity C-reactive protein (hsCRP) in patients with inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2008, 9, 140-143.	0.7	15
36	Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients. <i>Journal of Digestive Diseases</i> , 2008, 9, 219-224.	0.7	15
37	Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease – clinical relevance and pathophysiological mechanisms. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 621-637.	1.9	52

#	ARTICLE	IF	CITATIONS
38	Classifying Esophageal Motility by Pressure Topography Characteristics: A Study of 400 Patients and 75 Controls. <i>American Journal of Gastroenterology</i> , 2008, 103, 27-37.	0.2	390
39	European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 1-23.	0.6	470
40	Microinflammation in patients with Crohn's disease in clinical remission. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 310-314.	0.6	6
41	Updates on diagnosis: new tools? How can we measure activity?. <i>Digestive and Liver Disease Supplements</i> , 2008, 2, 5-6.	0.2	1
42	Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1091-1096.	0.9	61
43	Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices. <i>American Journal of Gastroenterology</i> , 2008, 103, 162-169.	0.2	534
44	Role of Biologics and Other Therapies in Stricturing Crohn's Disease: What Have We Learnt So Far?. <i>Digestion</i> , 2008, 77, 38-47.	1.2	31
45	Nicht-invasive Diagnostik kolorektaler Tumore – Hat der Guaiac-Test ausgedient? / Non-invasive detection of colorectal cancer – do we still need the guaiac-based fecal occult blood test?. <i>Laboratoriums Medizin</i> , 2008, 32, 158-167.	0.1	2
46	Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease?. <i>American Journal of Gastroenterology</i> , 2008, 103, 2007-2014.	0.2	195
47	Early Treatment of Acute Pyelonephritis in Children Fails to Reduce Renal Scarring: Data From the Italian Renal Infection Study Trials. <i>Pediatrics</i> , 2008, 122, 486-490.	1.0	131
48	Non-invasive detection of colorectal cancer – do we still need the guaiac-based fecal occult blood test? 1. <i>Laboratoriums Medizin</i> , 2008, 32, -.	0.1	0
49	New serological biomarkers of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 5115.	1.4	72
50	Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. <i>Gut</i> , 2009, 58, 859-868.	6.1	180
51	Clinical relevance of circulating midkine in ulcerative colitis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1085-90.	1.4	22
52	Bowel Ultrasound and Mucosal Healing in Ulcerative Colitis. <i>Digestive Diseases</i> , 2009, 27, 285-290.	0.8	53
53	Adiponectin deficiency does not affect development and progression of spontaneous colitis in IL-10 knockout mice. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G382-G387.	1.6	25
54	Biological markers in inflammatory bowel disease: Practical consideration for clinicians. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, S158-S173.	0.9	95
55	Paraoxonase-1 status in Crohn's disease and ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 93-99.	0.9	44

#	ARTICLE	IF	CITATIONS
56	Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-Induced Colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 341-352.	0.9	611
57	Predictive Value of Serologic Markers in a Population-based Norwegian Cohort with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 406-414.	0.9	48
58	Human neutrophil peptides 1-3 are useful biomarkers in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 909-917.	0.9	39
59	Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1746-1754.	0.9	97
60	Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1190-1198.	0.9	265
61	Ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1851-1858.	0.9	275
62	Cancer antigen 125 levels in inflammatory bowel diseases. <i>Journal of Clinical Laboratory Analysis</i> , 2009, 23, 244-248.	0.9	11
63	Increased Folate Intake with No Changes in Serum Homocysteine and Decreased Levels of C-Reactive Protein in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2009, 54, 627-633.	1.1	20
64	Red Cell Distribution Width for Assessment of Activity of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2009, 54, 842-847.	1.1	99
65	Correlation of Serum-Soluble Triggering Receptor Expressed on Myeloid Cells-1 with Clinical Disease Activity in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1525-1531.	1.1	65
66	Clinical significance of inflammatory markers. <i>Current Gastroenterology Reports</i> , 2009, 11, 360-367.	1.1	5
67	Diagnostic advances in inflammatory bowel disease (imaging and laboratory). <i>Current Gastroenterology Reports</i> , 2009, 11, 488-495.	1.1	19
68	Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 605-614.	1.9	40
69	Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1768-1774.	1.4	52
70	Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. <i>Clinical Biochemistry</i> , 2009, 42, 1602-1609.	0.8	34
71	A prospective evaluation of the diagnostic value of video capsule endoscopy in patients initially classified as irritable bowel syndrome. <i>European Journal of Internal Medicine</i> , 2009, 20, 48-52.	1.0	8
72	Presence and diagnosis of amebic infestation in Turkish patients with active ulcerative colitis. <i>European Journal of Internal Medicine</i> , 2009, 20, 545-547.	1.0	8
73	Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2009, 41, 56-66.	0.4	195

#	ARTICLE	IF	CITATIONS
74	Expression of the High-Affinity IgG Receptor FcRI (CD64) in Patients With Inflammatory Bowel Disease: A New Biomarker for Gastroenterologic Diagnostics. <i>American Journal of Gastroenterology</i> , 2009, 104, 102-109.	0.2	47
75	An overlooked indicator of disease activity in ulcerative colitis: Mean platelet volume. <i>Platelets</i> , 2009, 20, 277-281.	1.1	178
76	Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 577-594.	1.0	22
77	Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 729-752.	1.0	6
78	Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1168-1176.	0.8	16
79	Evaluation of Association Between Precolectomy Thrombocytosis and the Occurrence of Inflammatory Pouch Disorders. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1912-1918.	0.7	15
80	Predictive Value of Serologic Markers of Degree of Histologic Damage in Acute Uncomplicated Colonic Diverticulitis. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 702-706.	1.1	46
81	Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 340-345.	0.8	102
82	The Clinical Implication and Prediction of Diffuse Splenic FDG Uptake During Cancer Surveillance. <i>Clinical Nuclear Medicine</i> , 2010, 35, 759-763.	0.7	34
83	Impact of Autonomic Dysfunction on Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 272-279.	1.1	25
84	C-Reactive Protein and Disease Activity in Children with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 131-136.	1.1	25
85	Pediatric Inflammatory Bowel Disease in the Emergency Department. <i>Clinical Pediatric Emergency Medicine</i> , 2010, 11, 189-197.	0.4	0
86	Circulating midkine in Crohn's disease: Clinical implications. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 208-215.	0.9	30
87	Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 974-981.	0.9	44
88	New proteomic approaches for biomarker discovery in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1239-1246.	0.9	27
89	Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: Impact of anemia and treatment. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1467-1475.	0.9	39
90	Clinical utility of C-reactive protein in patients with ileal pouch anal anastomosis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1678-1684.	0.9	15
91	Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents. <i>Inflammatory Bowel Diseases</i> , 2010, 16, S1-S11.	0.9	16

#	ARTICLE	IF	CITATIONS
92	The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. <i>Journal of Infection</i> , 2010, 60, 409-416.	1.7	165
93	Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2010, 10, 118.	0.8	31
95	Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 551-558.	1.3	15
96	Serologic Markers: Impact on Early Diagnosis and Disease Stratification in Inflammatory Bowel Disease. <i>Postgraduate Medicine</i> , 2010, 122, 177-185.	0.9	15
97	Low-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 591-599.e1.	2.4	140
98	Diagnosis and assessment of Crohn's disease: the present and the future. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 757-766.	1.4	29
99	Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. <i>Medical Clinics of North America</i> , 2010, 94, 1-18.	1.1	33
100	Orally administered <i>L. lactis</i> secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. <i>Mucosal Immunology</i> , 2010, 3, 49-56.	2.7	231
101	Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 144-152.	0.6	139
102	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 7-27.	0.6	1,050
103	Assessment of activity of Crohn's disease by Doppler sonography of superior mesenteric artery flow. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 334-340.	0.6	22
104	Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study. <i>Digestive and Liver Disease</i> , 2010, 42, 191-195.	0.4	46
105	Evaluaci3n de la gesti3n en el laboratorio de gastroenterolog3a y significaci3n cl3nica de la calprotectina fecal en el contexto de 3ste. <i>Revista Del Laboratorio Cl3nico</i> , 2010, 3, 20-24.	0.1	0
107	Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis?: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2010, 105, 1150-1157.	0.2	110
108	Comparison of Oral Prednisone and Prednisone Combined with Metronidazole for Induction Therapy of Canine Inflammatory Bowel Disease: A Randomized-Controlled Trial. <i>Journal of Veterinary Internal Medicine</i> , 2010, 24, 269-277.	0.6	74
109	Potential urinary biomarkers of disease activity in Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 1440-1448.	0.6	10
110	Irritable Bowel Syndrome3Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?. <i>American Journal of Gastroenterology</i> , 2010, 105, 1789-1794.	0.2	204
111	Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: Calprotectin and IL-6 changes do not correspond to sRAGE changes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 294-299.	0.6	14

#	ARTICLE	IF	CITATIONS
112	Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease. <i>Medical Clinics of North America</i> , 2010, 94, 155-178.	1.1	4
113	Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. <i>BMJ: British Medical Journal</i> , 2010, 341, c3369-c3369.	2.4	554
114	Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 421-427.e1.	2.4	174
115	The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 140, 1817-1826.e2.	0.6	394
116	High prevalence of fatigue in inflammatory bowel disease: A case control study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 332-337.	0.6	39
117	C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 423-429.	0.6	63
118	Correlation of neutrophil and monocyte derived interleukin-1 receptor antagonist and interleukin-8 with colitis severity in the rabbit. <i>Cytokine</i> , 2011, 56, 508-514.	1.4	7
119	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?. <i>American Journal of Gastroenterology</i> , 2011, 106, 199-212.	0.2	356
120	Fecal calprotectin concentrations in alcoholic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 76-80.	0.8	7
121	Fecal calprotectin concentration and clinical response to certolizumab pegol in patients with active Crohn's disease: results from PRECISE 2. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S24-S25.	0.9	0
122	Update of fecal markers of inflammation in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1493-1499.	1.4	73
123	Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitis—a preliminary study. <i>European Radiology</i> , 2011, 21, 366-377.	2.3	26
124	Correlation of C-Reactive Protein with Clinical and Endoscopic Activity in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1801-1805.	1.1	46
125	Protein biomarkers in exfoliated cells collected from the human rectal mucosa: implications for colorectal disease detection and monitoring. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1287-1297.	1.0	13
126	Genes of intestinal <i>Escherichia coli</i> and their relation to the inflammatory activity in patients with ulcerative colitis and Crohn's disease. <i>Folia Microbiologica</i> , 2011, 56, 367-372.	1.1	13
127	Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 767-777.	0.9	68
128	Using metabolomic analysis to understand inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1021-1029.	0.9	56
131	Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 129-143.	1.4	47

#	ARTICLE	IF	CITATIONS
132	Is Moderate Red Wine Consumption Safe in Inactive Inflammatory Bowel Disease?. <i>Digestion</i> , 2011, 84, 238-244.	1.2	41
133	T cell prognosis for IBD. <i>Science-Business EXchange</i> , 2011, 4, 1168-1168.	0.0	0
134	Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 420-427.	0.6	31
135	Imaging of Pediatric Patients With Inflammatory Bowel Disease. <i>American Journal of Roentgenology</i> , 2012, 199, 907-915.	1.0	60
136	Genome-Wide Maps of Circulating miRNA Biomarkers for Ulcerative Colitis. <i>PLoS ONE</i> , 2012, 7, e31241.	1.1	95
137	Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2012, 18, 872.	1.4	81
138	Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2012, 13, 497-503.	0.7	11
139	Serum Metabolic Profiling in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2157-2165.	1.1	84
140	Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1079-82.	1.4	20
141	Biomarkers in inflammatory bowel disease: current practices and recent advances. <i>Translational Research</i> , 2012, 159, 313-325.	2.2	157
142	Comparison between a clinical activity index (Harvey-Bradshaw-Index), laboratory inflammation markers and quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound in Crohn's disease. <i>European Journal of Radiology</i> , 2012, 81, 1105-1109.	1.2	44
143	The versatile use of exhaled volatile organic compounds in human health and disease. <i>Journal of Breath Research</i> , 2012, 6, 027108.	1.5	257
144	Utility of fecal and serum anti- <i>Saccharomyces cerevisiae</i> antibodies in the diagnosis of Crohn's disease-like condition of the pouch. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1455-1463.	1.0	15
145	P094 Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S47.	0.6	0
146	Serum adenosine deaminase activity as a predictor of disease severity in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 102-107.	0.6	24
147	Intestinal superinfections in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 154-159.	0.6	48
148	Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 207-214.	0.6	57
149	Neuroimmune interactions in patients with inflammatory bowel diseases: Disease activity and clinical behavior based on Substance P serum levels. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 563-570.	0.6	23

#	ARTICLE	IF	CITATIONS
150	Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 852-860.	0.6	57
151	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 965-990.	0.6	715
152	Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease. <i>Digestive and Liver Disease</i> , 2012, 44, 466-470.	0.4	7
153	Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2012, 44, 897-903.	0.4	13
154	Calprotectin: a novel biomarker for the diagnosis of pleural effusion. <i>British Journal of Cancer</i> , 2012, 107, 1876-1882.	2.9	22
155	Assessment of wall inflammation and fibrosis in Crohn's disease: value of T1-weighted gadolinium-enhanced MR imaging. <i>Abdominal Imaging</i> , 2012, 37, 933-943.	2.0	28
156	Mean platelet volume: a controversial marker of disease activity in Crohn's disease. <i>European Journal of Medical Research</i> , 2012, 17, 27.	0.9	48
157	Longitudinal Change in Bone Mineral Density in a Population-Based Cohort of Patients with Inflammatory Bowel Disease. <i>Calcified Tissue International</i> , 2012, 91, 356-363.	1.5	23
158	Circulating Antibodies against Bacterial Wall Products: Are There Arguments for Early Immunosuppression?. <i>Digestive Diseases</i> , 2012, 30, 55-66.	0.8	61
160	Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 818-825.	0.9	26
161	High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: A marker for patient classification?. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1647-1654.	0.9	74
162	Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1894-1899.	0.9	243
163	Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2018-2025.	0.9	39
164	Association Between Red Cell Distribution Width and Disease Activity in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1033-1038.	1.1	104
165	Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn's Disease: Partial Benefit by Infliximab? A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1341-1348.	1.1	73
166	Evaluation of Fecal Myeloperoxidase as a Biomarker of Disease Activity and Severity in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1336-1340.	1.1	38
167	Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and results of histopathological scoring in ulcerative colitis. <i>International Journal of Colorectal Disease</i> , 2012, 27, 193-198.	1.0	38
168	Bioluminescence imaging for IL-1 β expression in experimental colitis. <i>Journal of Inflammation</i> , 2013, 10, 16.	1.5	15

#	ARTICLE	IF	CITATIONS
170	Assessment of causal link between psychological factors and symptom exacerbation in inflammatory bowel disease: a protocol for systematic review of prospective cohort studies. <i>Systematic Reviews</i> , 2013, 2, 8.	2.5	9
171	Current and Future Role of MR Enterography in the Management of Crohn Disease. <i>American Journal of Roentgenology</i> , 2013, 201, 56-64.	1.0	38
172	Histologic Markers of Inflammation in Patients With Ulcerative Colitis in Clinical Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 991-996.	2.4	109
173	Noninvasive evaluation of mucosal healing in inflammatory bowel diseases. <i>Clinical Journal of Gastroenterology</i> , 2013, 6, 1-7.	0.4	3
174	Optimising monitoring in the management of Crohn's disease: A physician's perspective. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 653-669.	0.6	96
175	Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. <i>Cellular Immunology</i> , 2013, 282, 66-70.	1.4	29
178	A Comprehensive Pathological Survey of Duodenal Biopsies from Dogs with Diet-Responsive Chronic Enteropathy. <i>Journal of Veterinary Internal Medicine</i> , 2013, 27, 862-874.	0.6	39
179	Neutrophil-Lymphocyte Ratio as a Predictor of Disease Severity in Ulcerative Colitis. <i>Journal of Clinical Laboratory Analysis</i> , 2013, 27, 72-76.	0.9	180
180	Serum calprotectin as a biomarker for Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e678-e683.	0.6	113
182	A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e641-e651.	0.6	135
183	Hand-held fractional exhaled nitric oxide measurements as a non-invasive indicator of systemic inflammation in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 644-648.	0.6	12
185	Mucosal healing in inflammatory bowel disease: Treatment efficacy and predictive factors. <i>Digestive and Liver Disease</i> , 2013, 45, 978-985.	0.4	50
186	S100A Expression and Interleukin-10 Polymorphisms Are Associated with Ulcerative Colitis and Diarrhea Predominant Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2314-2323.	1.1	24
187	Laboratory Evaluation of Inflammatory Bowel Disease. , 2013, , 175-187.		0
189	Faecal calprotectin concentrations in gastrointestinal diseases. <i>Journal of International Medical Research</i> , 2013, 41, 1357-1361.	0.4	25
190	Relationship Between Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels and Inflammatory Bowel Disease Type and Activity. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2587-2593.	1.1	28
191	Characterization of Relations Among Sleep, Inflammation, and Psychiatric Dysfunction in Depressed Youth With Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 57, 335-342.	0.9	46
192	Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-4.	0.7	40

#	ARTICLE	IF	CITATIONS
193	Preliminary Case-control Study to Evaluate Diagnostic Values of C-Reactive Protein and Erythrocyte Sedimentation Rate in Differentiating Active Crohn's Disease From Intestinal Lymphoma, Intestinal Tuberculosis and Behçet's Syndrome. <i>American Journal of the Medical Sciences</i> , 2013, 346, 467-472.	0.4	43
194	Capsule endoscopy: High negative predictive value in the long term despite a low diagnostic yield in patients with suspected Crohn's disease. <i>United European Gastroenterology Journal</i> , 2013, 1, 461-466.	1.6	32
195	Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2332-41.	3.3	88
196	<i>Bifidobacterium infantis</i> 35624 modulates host inflammatory processes beyond the gut. <i>Gut Microbes</i> , 2013, 4, 325-339.	4.3	342
197	Detection of Low-concentration Host mRNA Transcripts in Malawian Children at Risk for Environmental Enteropathy. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2013, 56, 66-71.	0.9	18
198	'Crohn's meanz Heinz': foreign body inflammatory mass mimicking Crohn's disease. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009603-bcr2013009603.	0.2	5
199	Serum Glycan Markers for Evaluation of Disease Activity and Prediction of Clinical Course in Patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2013, 8, e74861.	1.1	47
200	Gene Expression Analysis of Peripheral Cells for Subclassification of Pediatric Inflammatory Bowel Disease in Remission. <i>PLoS ONE</i> , 2013, 8, e79549.	1.1	12
201	Inflammatory Bowel Diseases. , 2014, , 1297-1304.		2
202	Physician Global Assessments or Blood tests do not Predict Mucosal Disease Activity in Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 325-329.	0.8	24
203	Biomarkers of Inflammatory Bowel Disease. <i>Disease Markers</i> , 2014, 2014, 1-11.	0.6	73
204	Correlation between Soluble Triggering Receptor Expressed on Myeloid Cells-1 and Endoscopic Activity in Intestinal Behçet's Disease. <i>Yonsei Medical Journal</i> , 2014, 55, 960.	0.9	4
205	Biomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies. <i>World Journal of Gastroenterology</i> , 2014, 20, 3231.	1.4	86
206	Correlation between gut pathogens and fecal calprotectin levels in young children with acute diarrhea. <i>Paediatrica Indonesiana</i> , 2014, 54, 193.	0.0	4
207	Inflammatory Bowel Disease Alters Intestinal Bile Acid Transporter Expression. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1423-1431.	1.7	70
208	Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: Proof of principle study. <i>Journal of Crohn's and Colitis</i> , 2014, , .	0.6	36
209	Matrix Metalloproteinase-9: Its Interplay with Angiogenic Factors in Inflammatory Bowel Diseases. <i>Disease Markers</i> , 2014, 2014, 1-8.	0.6	43
210	Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1397-1397.	0.6	0

#	ARTICLE	IF	CITATIONS
211	C-reactive protein in Crohn's disease: how informative is it?. Expert Review of Gastroenterology and Hepatology, 2014, 8, 393-408.	1.4	19
213	Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice. Immunology, 2014, 143, 416-427.	2.0	38
214	Decreased Serum Fetuin-A Levels and Active Inflammatory Bowel Disease. American Journal of the Medical Sciences, 2014, 348, 47-51.	0.4	12
215	Clinical pharmacology of AMG 181, a gut-specific human anti-IL-4 antibody, for treating inflammatory bowel diseases. British Journal of Clinical Pharmacology, 2014, 78, 1315-1333.	1.1	32
216	C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. Journal of Gastroenterology, 2014, 49, 254-262.	2.3	56
217	Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis. Digestive Diseases and Sciences, 2014, 59, 829-837.	1.1	69
218	The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. Cancer Causes and Control, 2014, 25, 409-418.	0.8	10
220	Predictors of response to Infliximab in children with luminal Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 739-746.	0.6	27
221	Inflammatory Bowel Diseases. , 2014, , 873-888.		0
222	Ulcerative Colitis. Mayo Clinic Proceedings, 2014, 89, 1553-1563.	1.4	236
223	Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study. Alimentary Pharmacology and Therapeutics, 2014, 40, 498-507.	1.9	47
225	Fecal Calprotectin-Guided Dosing of Mesalamine in Ulcerative Colitis: Concept Proved but More Data Needed. Clinical Gastroenterology and Hepatology, 2014, 12, 1894-1896.	2.4	2
227	High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. Journal of Crohn's and Colitis, 2014, 8, 129-136.	0.6	76
228	A Sonographic Lesion Index for Crohn's Disease Helps Monitor Changes in Transmural Bowel Damage During Therapy. Clinical Gastroenterology and Hepatology, 2014, 12, 2071-2077.	2.4	48
229	Serum Inflammatory Markers and Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2014, 12, 1342-1348.e1.	2.4	38
230	Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. Journal of Gastroenterology, 2014, 49, 638-645.	2.3	160
231	Slight Increases in the Disease Activity Index and Platelet Count Imply the Presence of Active Intestinal Lesions in C-reactive Protein-negative Crohn's Disease Patients. Internal Medicine, 2014, 53, 1905-1911.	0.3	16
232	Erythrocyte Sedimentation Rate and C-Reactive Protein: How Best to Use Them in Clinical Practice. Pediatric Annals, 2014, 43, 417-420.	0.3	71

#	ARTICLE	IF	CITATIONS
233	Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World Journal of Gastroenterology, 2015, 21, 21.	1.4	160
234	An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterology, 2015, 15, 163.	0.8	26
235	Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial. Trials, 2015, 16, 271.	0.7	19
236	The PRECious trial PREdiction of Complications, a step-up approach, CRP first followed by CT-scan imaging to ensure quality control after major abdominal surgery: study protocol for a stepped-wedge trial. Trials, 2015, 16, 382.	0.7	11
237	Biomarkers of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	25
238	Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity. Inflammatory Bowel Diseases, 2015, 21, 1769-1775.	0.9	60
239	Review article: breath analysis in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2015, 41, 329-341.	1.9	50
240	Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease. Acta Biochimica Polonica, 2015, 62, 541-545.	0.3	17
241	Laboratory markers in ulcerative colitis: Current insights and future advances. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 13.	0.5	80
242	Intestinal Microbiota Signatures Associated with Inflammation History in Mice Experiencing Recurring Colitis. Frontiers in Microbiology, 2015, 6, 1408.	1.5	106
243	FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arquivos De Gastroenterologia, 2015, 52, 50-54.	0.3	17
244	Fecal Calprotectin Concentrations in Healthy Children Aged 1-18 Months. PLoS ONE, 2015, 10, e0119574.	1.1	59
245	Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease. Mediators of Inflammation, 2015, 2015, 1-9.	1.4	46
246	Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Molecular Diagnosis and Therapy, 2015, 19, 141-158.	1.6	7
247	Phenotypic characterisation of Crohn's disease severity. , 2015, 2015, 7023-6.		5
248	Serum REG3alpha and C-Reactive Protein Levels in Crohn's Disease Patients Undergoing Immunoablation and Autologous Hemopoietic Stem Cell Transplantation in the ASTIC Trial. Digestion, 2015, 92, 83-89.	1.2	0
249	The relationship between the neutrophil-lymphocyte ratio and disease activity in patients with ulcerative colitis. Kaohsiung Journal of Medical Sciences, 2015, 31, 585-590.	0.8	47
250	Clinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia. Digestive Diseases and Sciences, 2015, 60, 1375-1381.	1.1	28

#	ARTICLE	IF	CITATIONS
251	Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 107-113.	0.7	12
252	Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis?. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 262-265.	1.0	84
253	Plateletcrit: A sensitive biomarker for evaluating disease activity in Crohn's disease with low hs-CRP. <i>Journal of Digestive Diseases</i> , 2015, 16, 118-124.	0.7	52
254	Investigating young adults with chronic diarrhoea in primary care. <i>BMJ</i> , The, 2015, 350, h573.	3.0	2
255	Diagnosis and monitoring of postoperative recurrence in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 55-66.	1.4	19
256	Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2419-2426.	1.1	22
257	No Association Between Serum Adenosine Deaminase Activity and Disease Activity in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1755-1760.	1.1	6
258	Genetic polymorphism in <i>ATG16L1</i> gene influences the response to adalimumab in Crohn's disease patients. <i>Pharmacogenomics</i> , 2015, 16, 191-204.	0.6	48
259	Impact of disease location on fecal calprotectin levels in Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 841-847.	0.6	93
260	Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3085-3091.	1.1	63
261	The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 1001-1012.	0.2	123
262	Biomarkers of Inflammation in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1275-1285.e2.	0.6	287
263	Anti-inflammatory effects of Brazilian ginseng (<i>Pfaffia paniculata</i>) on TNBS-induced intestinal inflammation: Experimental evidence. <i>International Immunopharmacology</i> , 2015, 28, 459-469.	1.7	10
264	Clinical Utility of Biomarkers in IBD. <i>Current Gastroenterology Reports</i> , 2015, 17, 26.	1.1	23
265	Fecal calprotectin in systemic sclerosis and review of the literature. <i>Autoimmunity Reviews</i> , 2015, 14, 547-554.	2.5	60
266	Value of Red Cell Distribution Width for Assessing Disease Activity in Crohn's Disease. <i>American Journal of the Medical Sciences</i> , 2015, 349, 42-45.	0.4	9
267	Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: Clinical and laboratory outcomes. <i>Veterinary Journal</i> , 2015, 206, 385-390.	0.6	61
268	Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 863-872.	0.6	69

#	ARTICLE	IF	CITATIONS
269	C-reaktives Protein und die Akute-Phase-Reaktion bei geriatrischen Patienten. Zeitschrift Fur Gerontologie Und Geriatrie, 2015, 48, 595-600.	0.8	18
270	The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity. European Journal of Internal Medicine, 2015, 26, 623-627.	1.0	10
271	Evaluation of the concordance between biological markers and clinical activity in inflammatory bowel disease. Medicina Clínica (English Edition), 2015, 144, 9-13.	0.1	0
272	C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterology, 2015, 15, 103.	0.8	28
273	Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Internal and Emergency Medicine, 2015, 10, 321-328.	1.0	23
274	Development and validation of a new disease severity index: the Inflammatory Bowel Disease Index (IBDEX). Frontline Gastroenterology, 2015, 6, 161-168.	0.9	8
276	Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1042-1050.e2.	2.4	240
277	Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2015, 13, 635-642.	2.4	45
278	Current application of proteomics in biomarker discovery for inflammatory bowel disease. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 27.	0.5	36
279	Infliximab Combined with Enteral Nutrition for Managing Crohn's Disease Complicated with Intestinal Fistulas. Gastroenterology Research and Practice, 2016, 2016, 1-6.	0.7	4
280	Usefulness of Endoscopic Indices in Determination of Disease Activity in Patients with Crohn's Disease. Gastroenterology Research and Practice, 2016, 2016, 1-12.	0.7	6
281	Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. Intestinal Research, 2016, 14, 152.	1.0	12
282	Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosnian Journal of Basic Medical Sciences, 2016, 16, 71-4.	0.6	24
283	Baseline Characteristics and Disease Phenotype in Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 50-55.	0.9	14
284	Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy. Colorectal Disease, 2016, 18, 696-702.	0.7	2
285	Value of Fecal Calprotectin as a Biomarker for Juvenile Polyps in Children Investigated With Colonoscopy. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 43-46.	0.9	24
286	C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn's disease. Cell Death Discovery, 2016, 2, 16032.	2.0	15
287	Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2016, 22, 2016-2022.	0.9	32

#	ARTICLE	IF	CITATIONS
288	Inflammatory bowel disease in Chinese children: A retrospective analysis of 49 cases. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 3363-3368.	0.8	3
289	Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn's Disease. <i>BMC Gastroenterology</i> , 2016, 16, 126.	0.8	22
290	Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 17-26.	0.7	23
291	Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2121-2126.	0.9	90
292	ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?. <i>Digestive Diseases</i> , 2016, 34, 90-97.	0.8	56
293	Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. <i>Journal of Gastroenterology</i> , 2016, 51, 531-547.	2.3	23
294	B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2608-2618.	1.1	29
295	IBD Diagnosis and Evaluation. , 2016, , 771-786.		0
296	A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF- α Drug Adalimumab: Contribution of <i>ATG5</i> , <i>NFKB1</i> and <i>CRP</i> Genes to Pharmacodynamic Variability. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 296-309.	1.0	19
297	Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. <i>European Journal of Pediatrics</i> , 2016, 175, 1335-1342.	1.3	22
298	Biomarkers in Search of Precision Medicine in IBD. <i>American Journal of Gastroenterology</i> , 2016, 111, 1682-1690.	0.2	45
299	Serum Immune System Biomarkers Neopterin and Interleukin-10 Are Strongly Related to Tryptophan Metabolism in Healthy Young Adults. <i>Journal of Nutrition</i> , 2016, 146, 1801-1806.	1.3	17
300	Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1239-1240.	1.9	1
301	Remission maintained by monotherapy after biological+immunosuppressive combination for Crohn's disease in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 112-118.	1.4	10
302	Magnetic Resonance Enterography in the Study of Patients with Crohn's Disease: Which Findings Are More Likely to Change Patient Management?. <i>Canadian Association of Radiologists Journal</i> , 2016, 67, 387-394.	1.1	3
303	The fecal microbiota as a biomarker for disease activity in Crohn's disease. <i>Scientific Reports</i> , 2016, 6, 35216.	1.6	63
304	Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 17-26.	0.7	10
305	Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. <i>BMC Gastroenterology</i> , 2016, 16, 103.	0.8	30

#	ARTICLE	IF	CITATIONS
306	Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2665-2671.	0.9	27
307	Risk factors associated with portomesenteric venous thrombosis in patients undergoing restorative proctocolectomy for medically refractory ulcerative colitis. <i>Colorectal Disease</i> , 2016, 18, 393-399.	0.7	19
308	Can Red Cell Distribution Width Be Used as a Marker of Crohn's Disease Activity?. <i>GE Portuguese Journal of Gastroenterology</i> , 2016, 23, 6-12.	0.3	10
309	Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. <i>BMC Gastroenterology</i> , 2016, 16, 47.	0.8	42
310	Growth Pattern in Paediatric Crohn Disease Is Related to Inflammatory Status. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 63, 637-643.	0.9	32
311	Effect of oral diclofenac intake on faecal calprotectin. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 28-32.	0.6	28
312	Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 596-611.	1.9	102
313	Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 835-841.	0.6	13
314	Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2016, 51, 434-446.	2.3	56
315	A novel sol particle immunoassay for fecal calprotectin in inflammatory bowel disease patients. <i>Clinica Chimica Acta</i> , 2016, 456, 1-6.	0.5	9
316	Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 786-794.	0.6	70
317	Colitis ulcerosa. <i>Medicine</i> , 2016, 12, 227-241.	0.0	0
318	Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis. <i>Pediatrics</i> , 2016, 137, .	1.0	50
319	Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 442-447.	0.6	15
320	Extending landscape of volatile metabolites as novel diagnostic biomarkers of inflammatory bowel disease – a review. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 385-392.	0.6	14
321	The Place of Calprotectin, Lactoferrin, and High-Mobility Group Box 1 Protein on Diagnosis of Acute Appendicitis with Children. <i>Indian Journal of Surgery</i> , 2017, 79, 131-136.	0.2	11
322	Does calprotectin level identify a subgroup among patients suffering from irritable bowel syndrome? Results of a prospective study. <i>United European Gastroenterology Journal</i> , 2017, 5, 261-269.	1.6	19
323	Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 951-960.	1.9	29

#	ARTICLE	IF	CITATIONS
325	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2017, 82, 46-84.	0.1	7
326	Laboratory Evaluation, Including Novel Diagnostic Markers. , 2017, , 233-242.		1
327	Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2017, 40, 125-131.	0.0	8
328	A microbial signature for Crohn's disease. <i>Gut</i> , 2017, 66, 813-822.	6.1	657
329	Proteomics and irritable bowel syndrome. <i>Expert Review of Proteomics</i> , 2017, 14, 461-468.	1.3	5
330	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 649-670.	0.6	1,324
331	Effects of <i>Urtica dioica</i> leaf extract on inflammation, oxidative stress, ESR, blood cell count and quality of life in patients with inflammatory bowel disease. <i>Journal of Herbal Medicine</i> , 2017, 9, 32-41.	1.0	10
332	Inflammatory bowel diseases. <i>Medicine (United States)</i> , 2017, 96, e6329.	0.4	12
333	Ectopic Expression of Innate Immune Protein, Lipocalin-2, in <i>Lactococcus lactis</i> Protects Against Gut and Environmental Stressors. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1120-1132.	0.9	11
334	Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal BehÃetâ€™s Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1953-1962.	1.1	12
335	Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 858-865.	0.9	25
336	MR Enterography in Crohnâ€™s disease complicated with enteroenteric fistula. <i>European Journal of Radiology</i> , 2017, 94, 101-106.	1.2	10
337	Crohn Disease: Epidemiology, Diagnosis, and Management. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1088-1103.	1.4	292
338	Delivery and feeding mode affects fecal calprotectin levels in infants < 7 months old. <i>Early Human Development</i> , 2017, 108, 45-48.	0.8	21
339	Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohnâ€™s Disease. <i>American Journal of the Medical Sciences</i> , 2017, 353, 439-444.	0.4	9
340	The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohnâ€™s disease. <i>BMC Gastroenterology</i> , 2017, 17, 40.	0.8	7
341	Transient Receptor Potential Channels in Intestinal Inflammation: What Is the Impact of Cigarette Smoking?. <i>Pathobiology</i> , 2017, 84, 1-15.	1.9	23
342	A Novel Model for Predicting Incident Moderate to Severe Anemia and Iron Deficiency in Patients with Newly Diagnosed Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1295-1304.	1.1	4

#	ARTICLE	IF	CITATIONS
345	Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista De Gastroenterología De México, 2017, 82, 46-84.	0.4	22
346	Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy. Inflammatory Bowel Diseases, 2017, 23, 2027-2034.	0.9	36
347	Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. Journal of Clinical Pathology, 2017, 70, 1049-1056.	1.0	18
348	Luminally expressed gastrointestinal biomarkers. Expert Review of Gastroenterology and Hepatology, 2017, 11, 1119-1134.	1.4	10
349	Microbiomarkers in inflammatory bowel diseases: caveats come with caviar. Gut, 2017, 66, 1734-1738.	6.1	47
350	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn. Gastroenterología Y Hepatología, 2017, 40, 472-483.	0.2	27
351	Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 261-271.	0.9	11
352	Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. Scientific Reports, 2017, 7, 7458.	1.6	54
353	Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice. Digestion, 2017, 96, 119-126.	1.2	12
354	Dynamics of neutrophil gelatinase-associated lipocalin plasma and cerebrospinal fluid concentrations in older males. European Journal of Clinical Investigation, 2017, 47, e12853.	1.7	4
355	Skin Manifestations of Inflammatory Bowel Disease. Clinical Reviews in Allergy and Immunology, 2017, 53, 413-427.	2.9	88
356	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. Gastroenterología Y Hepatología (English Edition), 2017, 40, 472-483.	0.0	4
357	State of the Art and Future Predictions: Isn't There a Test for That? Diagnosing IBD. Clinical Gastroenterology, 2017, , 45-59.	0.0	0
358	Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF. Digestive and Liver Disease, 2017, 49, 29-33.	0.4	8
359	Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, 84-91.	0.6	100
360	Calprotectina fecal, marcador eficaz en la diferenciación de enfermedades inflamatorias intestinales y trastornos funcionales gastrointestinales. Gastroenterología Y Hepatología, 2017, 40, 125-131.	0.2	14
361	A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. Journal of Clinical Laboratory Analysis, 2017, 31, e22061.	0.9	14
362	Urinary potassium is a potential biomarker of disease activity in Ulcerative colitis and displays in vitro immunotolerant role. Scientific Reports, 2017, 7, 18068.	1.6	2

#	ARTICLE	IF	CITATIONS
363	Bacterial translocation markers in liver cirrhosis. <i>Annals of Gastroenterology</i> , 2017, 30, 486-497.	0.4	60
364	Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 228-235.	0.8	12
365	Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease. <i>PLoS ONE</i> , 2017, 12, e0179710.	1.1	18
366	Diagnostic test strategies in children at increased risk of inflammatory bowel disease in primary care. <i>PLoS ONE</i> , 2017, 12, e0189111.	1.1	10
367	Psychological wellbeing and physical activity in children and adolescents with inflammatory bowel disease compared to healthy controls. <i>BMC Gastroenterology</i> , 2017, 17, 160.	0.8	22
368	Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. <i>BMC Medicine</i> , 2017, 15, 184.	2.3	34
369	Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 3356.	1.4	125
370	Prognostic value of preoperative neutrophil-to-lymphocyte ratio in Crohn's disease. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 398-403.	1.0	13
371	Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 861-867.	0.8	15
372	Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1268-1275.e2.	2.4	42
373	Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 277-285.	0.9	16
374	Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine. <i>Biomedicine and Pharmacotherapy</i> , 2018, 100, 8-14.	2.5	16
375	Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 990-997.	1.4	27
376	Serum amyloid A level correlated with endoscopic findings in patients with Crohn's disease—Possible biomarker for evaluating mucosal healing. <i>Digestive and Liver Disease</i> , 2018, 50, 553-558.	0.4	12
377	Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 353-359.	0.4	28
378	The importance of calprotectin for differentiating organic inflammatory disease and avoiding unnecessary procedures in paediatrics. <i>Medicina Clínica</i> , 2018, 151, 231-235.	0.3	0
379	Alterations in lipid, amino acid, and energy metabolism distinguish Crohn's disease from ulcerative colitis and control subjects by serum metabolomic profiling. <i>Metabolomics</i> , 2018, 14, 17.	1.4	137
380	Total α -1-acid glycoprotein determination in serum samples using disposable screen-printed electrodes and osmium (VI) as electrochemical tag. <i>Talanta</i> , 2018, 180, 206-210.	2.9	17

#	ARTICLE	IF	CITATIONS
381	Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 78-92.	0.9	42
382	Inverse Association Between Circulating Monocyte-Platelet Complexes and Inflammation in Ulcerative Colitis Patients. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 818-828.	0.9	10
383	Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease. <i>Journal of Breath Research</i> , 2018, 12, 016006.	1.5	32
384	Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 229-234.	1.1	35
385	Sliding-strip microfluidic device enables ELISA on paper. <i>Biosensors and Bioelectronics</i> , 2018, 99, 77-84.	5.3	110
386	Utility of Fecal Calprotectin in Evaluation of Chronic Gastrointestinal Symptoms in Primary Care. <i>Clinical Pediatrics</i> , 2018, 57, 1058-1063.	0.4	11
387	Quality, Safety, and Practical Considerations of Using Biologic Therapies. , 2018, , 315-328.		0
388	Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	8
389	Associations among body composition, inflammatory profile and disease extent in ulcerative colitis patients. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 133-139.	0.3	10
390	Elevated urinary orosomucoid excretion as a novel biomarker in Crohn's disease. <i>European Journal of Clinical Investigation</i> , 2018, 49, e13054.	1.7	7
391	Analysis and Hierarchical Clustering of Blood Results Before Diagnosis in Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 469-475.	0.9	9
392	Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-10.	0.7	18
393	Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs. <i>Journal of Veterinary Internal Medicine</i> , 2018, 32, 1495-1508.	0.6	58
394	Sniffing out causes of gastrointestinal disorders: a review of volatile metabolomic biomarkers. <i>Biomarkers in Medicine</i> , 2018, 12, 1139-1148.	0.6	6
395	Sleep Quality in Ulcerative Colitis: Associations with Inflammation, Psychological Distress, and Quality of Life. <i>International Journal of Behavioral Medicine</i> , 2018, 25, 517-525.	0.8	24
396	The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 825-830.	0.6	35
397	The Roles of Antimicrobial Peptides in the Regulation of Gastrointestinal Microbiota and Innate Immunity. , 2018, , 35-60.		0
398	Fecal markers in the management of inflammatory bowel disease. <i>Postgraduate Medicine</i> , 2018, 130, 597-606.	0.9	12

#	ARTICLE	IF	CITATIONS
399	Urine and stool analyses. , 2018, , 181-192.		0
400	The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases. <i>Frontiers in Pediatrics</i> , 2018, 5, 292.	0.9	16
401	Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 829-843.	0.6	80
402	Differential diagnosis of inflammatory bowel disease: imitations and complications. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 644-653.	3.7	88
403	Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1984-1989.	1.4	20
404	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 144-164K.	0.6	958
405	Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort. <i>Clinical and Experimental Immunology</i> , 2019, 198, 131-140.	1.1	5
406	New markers in ulcerative colitis. <i>Clinica Chimica Acta</i> , 2019, 497, 141-146.	0.5	29
407	Ulcerative Colitis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1357-1373.	1.4	227
408	Clinical characteristics and outcome of fistulizing Crohn's disease: One single-center experience in Taiwan. <i>Advances in Digestive Medicine</i> , 2019, 6, 165-171.	0.1	0
409	A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2019, 6, 251.	1.2	37
410	Fecal calprotectin in children with familial Mediterranean fever in the attack-free period. <i>Pediatrics International</i> , 2019, 61, 1140-1145.	0.2	4
411	Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1226-1232.	0.6	2
412	Laboratory Medicine and Diagnostic Pathology. , 2019, , 255-313.		3
413	The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Nutrients</i> , 2019, 11, 293.	1.7	86
414	Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2019, 64, 265-270.	0.6	17
415	Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. <i>Autoimmunity Highlights</i> , 2019, 10, 4.	3.9	44
416	Crohn's disease: A retrospective analysis between computed tomography enterography, colonoscopy, and histopathology. <i>Radiography</i> , 2019, 25, 349-358.	1.1	9

#	ARTICLE	IF	CITATIONS
417	Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases. <i>Gastroenterology Clinics of North America</i> , 2019, 48, 237-258.	1.0	3
418	Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity. <i>British Journal of Pharmacology</i> , 2019, 176, 2209-2226.	2.7	75
419	Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn's disease. <i>Clinical and Experimental Immunology</i> , 2019, 197, 111-129.	1.1	51
420	Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology. <i>Cell Reports</i> , 2019, 26, 2704-2719.e6.	2.9	191
421	Integrative analysis of Paneth cell proteomic and transcriptomic data from intestinal organoids reveals functional processes dependent on autophagy. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	20
422	Serum Resolvin E1 Levels and Its Relationship with Disease Activity in Ulcerative Colitis. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-5.	0.7	5
423	Prediction of treatment outcome and relapse in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 667-677.	1.3	15
424	The Influence of Maternal-Foetal Parameters on Concentrations of Zonulin and Calprotectin in the Blood and Stool of Healthy Newborns during the First Seven Days of Life. An Observational Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 473.	1.0	11
425	Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1306-1312.	0.8	12
426	Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 235-242.	1.0	4
427	The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 69, 75-81.	0.9	2
428	Low serum bilirubin, albumin, and uric acid levels in patients with Crohn's disease. <i>Medicine (United States)</i> , 2019, 98, 1-11.	0.4	21
429	Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1173-1183.	0.8	5
430	Involvement of midkine in autoimmune and autoinflammatory diseases. <i>Modern Rheumatology</i> , 2019, 29, 567-571.	0.9	16
431	A Novel Predictive Nomogram for Early Endoscopic Recurrence after Intestinal Resection for Crohn's Disease. <i>Digestion</i> , 2019, 100, 269-276.	1.2	8
432	Biochemical Markers, Genotype, and Inflammation in Pediatric Inflammatory Bowel Disease: A Danish Population-Based Study. <i>Digestive Diseases</i> , 2019, 37, 140-146.	0.8	11
433	Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-24.	0.7	20
434	Longitudinal analysis of molecular alteration in serum samples of dextran sodium sulfate-induced colitis mice by using infrared spectroscopy. <i>Infrared Physics and Technology</i> , 2019, 97, 33-37.	1.3	6

#	ARTICLE	IF	CITATIONS
435	Disposable carbon nanotube scaffold films for fast and reliable assessment of total Î±1-acid glycoprotein in human serum using adsorptive transfer stripping square wave voltammetry. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 1887-1894.	1.9	6
436	GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 389-394.	0.6	32
437	The Costs of Living Together: Immune Responses to the Microbiota and Chronic Gut Inflammation. <i>Applied and Environmental Microbiology</i> , 2019, 85, .	1.4	4
438	Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 961-969.	0.9	9
439	Autologous Exosome Transfer: A New Personalised Treatment Concept to Prevent Colitis in a Murine Model. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 841-855.	0.6	24
440	Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 545-553.	1.1	24
441	Spanish Pediatric Inflammatory Bowel Disease Diagnostic Delay Registry: SPIDER Study From Sociedad EspaÃ±ola de GastroenterologÃa, HepatologÃa y NutriciÃ³n PediÃ¡trica. <i>Frontiers in Pediatrics</i> , 2020, 8, 584278.	0.9	10
442	Revisiting the gutâ€“joint axis: links between gut inflammation and spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 415-433.	3.5	106
443	Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1106-1115.	0.8	12
444	A Sweat-based Wearable Enabling Technology for Real-time Monitoring of IL-1Î² and CRP as Potential Markers for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1533-1542.	0.9	56
445	Intra-Individual and Seasonal Variation of Selected Biomarkers for Internal Load Monitoring in U-19 Soccer Players. <i>Frontiers in Physiology</i> , 2020, 11, 838.	1.3	10
446	What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?. <i>International Journal of Colorectal Disease</i> , 2020, 35, 2249-2255.	1.0	2
447	Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. <i>JHEP Reports</i> , 2020, 2, 100151.	2.6	26
448	New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies. <i>Proteomes</i> , 2020, 8, 18.	1.7	10
449	Biomarkers of Crohnâ€™s Disease to Support the Development of New Therapeutic Interventions. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1498-1508.	0.9	10
450	The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 191-199.	0.8	3
451	Growth and Puberty in Children with Inflammatory Bowel Diseases. <i>Biomedicines</i> , 2020, 8, 458.	1.4	22
452	Neutrophilic HGF-MET Signalling Exacerbates Intestinal Inflammation. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1748-1758.	0.6	12

#	ARTICLE	IF	CITATIONS
453	MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00134.	1.3	16
454	A 12-month pilot study outcomes of vagus nerve stimulation in Crohn's disease. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13911.	1.6	76
456	Crohn's disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 22.	18.1	420
457	Flos Ionicerae flavonoids attenuate experimental ulcerative colitis in rats via suppression of NF- κ B signaling pathway. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 2481-2494.	1.4	29
458	Red cell distribution width as a marker of activity in inflammatory bowel disease: a narrative review. <i>Annals of Gastroenterology</i> , 2020, 33, 348-354.	0.4	13
459	Title: Human Serum/Plasma Glycoprotein Analysis by 1H-NMR, an Emerging Method of Inflammatory Assessment. <i>Journal of Clinical Medicine</i> , 2020, 9, 354.	1.0	57
460	Microbiome-skin-brain axis: A novel paradigm for cutaneous wounds. <i>Wound Repair and Regeneration</i> , 2020, 28, 282-292.	1.5	12
461	Measuring Vitamin D Status in Chronic Inflammatory Disorders: How does Chronic Inflammation Affect the Reliability of Vitamin D Metabolites in Patients with IBD?. <i>Journal of Clinical Medicine</i> , 2020, 9, 547.	1.0	12
462	Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2020, 7, 8.	1.2	12
463	A randomized controlled trial investigating the effect of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols on the intestinal microbiome and inflammation in patients with ulcerative colitis: study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 201.	0.7	17
464	Prevalence and Effect of Intestinal Infections Detected by a PCR-Based Stool Test in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3287-3296.	1.1	16
465	Probiotics with ameliorating effects on the severity of skin inflammation in psoriasis: Evidence from experimental and clinical studies. <i>Journal of Cellular Physiology</i> , 2020, 235, 8925-8937.	2.0	20
466	Serum Biomarkers for Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2020, 7, 123.	1.2	104
467	Engineered bacteria to report gut function: technologies and implementation. <i>Current Opinion in Microbiology</i> , 2021, 59, 24-33.	2.3	24
468	Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2374-2384.	1.1	6
469	Metabolomic Signatures in Pediatric Crohn's Disease Patients with Mild or Quiescent Disease Treated with Partial Enteral Nutrition: A Feasibility Study. <i>SLAS Technology</i> , 2021, 26, 165-177.	1.0	7
470	Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?. <i>Digestive Diseases</i> , 2021, 39, 190-203.	0.8	37
471	Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	1.4	33

#	ARTICLE	IF	CITATIONS
472	Intestinal Obstruction, as the First Presentation of Crohn's Disease, in an Adolescent. <i>Journal of Clinical and Medical Images and Short Reports</i> , 2021, 05, .	0.0	0
473	Assessment of the usefulness of imaging studies and biomarkers in the activity of Crohn's disease. <i>Przegląd Gastroenterologiczny</i> , 2021, 16, 15-22.	0.3	0
474	Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role?. <i>Current Pathobiology Reports</i> , 2021, 9, 9-32.	1.6	3
475	Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity. <i>Archives of Medical Science</i> , 2021, 17, 252-257.	0.4	5
476	Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Visceral Medicine</i> , 2021, 37, 338-348.	0.5	8
477	Issues of inflammatory bowel disease management in primary care.. <i>Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini</i> , 2021, 2021, 109-115.	0.0	0
478	How Valuable are Noninvasive Tests as Indicators of IBD Activity and Severity in the Primary Health Care? Afro-Egyptian Journal of Infectious and Endemic Diseases, 2021, .	0.1	0
479	(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. <i>Molecules</i> , 2021, 26, 1843.	1.7	21
480	Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review. <i>World Journal of Gastroenterology</i> , 2021, 27, 1828-1840.	1.4	16
481	Is Fecal Calprotectin a Useful Marker for Small Bowel Crohn Disease?. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 73, 242-246.	0.9	14
482	Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. <i>Journal of Gastroenterology</i> , 2021, 56, 560-569.	2.3	34
483	WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. <i>World Journal of Emergency Surgery</i> , 2021, 16, 23.	2.1	29
484	Associations between high-sensitivity C-reactive protein and non-communicable diseases in an Asian population: findings from the IFLS study. <i>Biomarkers</i> , 2021, 26, 548-556.	0.9	2
485	Unlocking the causal link of metabolically different adiposity subtypes with brain volumes and the risks of dementia and stroke: A Mendelian randomization study. <i>Neurobiology of Aging</i> , 2021, 102, 161-169.	1.5	18
486	Fecal microbiota transfer for refractory intestinal graft-versus-host disease Experience from two German tertiary centers. <i>European Journal of Haematology</i> , 2021, 107, 229-245.	1.1	20
487	Long-term Trajectories of C-Reactive Protein Among Men Living With and Without HIV Infection in the Multicenter AIDS Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, , .	1.7	3
488	Dynamics of leukocytic blood parameters depending on the activity of inflammatory bowel disease in children. <i>Russian Pediatric Journal</i> , 2021, 24, 148-156.	0.0	0
489	The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 3362.	1.0	6

#	ARTICLE	IF	CITATIONS
490	The method for diagnosing the activity of inflammatory bowel diseases based on a combination of electrical and viscoelastic parameters of erythrocytes and the level of fecal calprotectin. Eksperimental'naya i Klinicheskaya Gastroenterologiya, 2021, 1, 40-49.	0.1	1
492	Stem Cell Therapy for the Treatment of Crohn's Disease; Current Obstacles and Future Hopes. Current Stem Cell Research and Therapy, 2022, 17, 727-733.	0.6	1
493	Elevated fecal calprotectin is linked to psychosocial complexity in pediatric functional abdominal pain disorders. BMC Research Notes, 2021, 14, 360.	0.6	1
494	Predictors of the CD24/CD11b Biomarker among Healthy Subjects. Journal of Personalized Medicine, 2021, 11, 939.	1.1	3
495	Potassium bromate (KBrO3) modulates oxidative stress and inflammatory biomarkers in sodium hydroxide (NaOH) induced Crohn's colitis in Wistar rats. Canadian Journal of Physiology and Pharmacology, 2021, 99, 989-999.	0.7	1
496	USEFULNESS OF PERIPHERAL BLOOD MONOCYTE COUNT TO PREDICT RELAPSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE LONGITUDINAL COHORT STUDY.. Revista Espanola De Enfermedades Digestivas, 2021, , .	0.1	3
497	Comparative study between different methods for the determination of fecal calprotectin. Revista De Medicina De Laboratorio, 2021, , .	0.0	0
498	Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clinical Pharmacology and Therapeutics, 2021, 109, 1639-1647.	2.3	38
500	Comparison of two human organoid models of lung and intestinal inflammation reveals Toll-like receptor signalling activation and monocyte recruitment. Clinical and Translational Immunology, 2020, 9, e1131.	1.7	31
501	Molecular Profiling of IBD Subtypes and Therapy Responses. , 2019, , 157-182.		1
502	Laboratory Medicine and Diagnostic Pathology. , 2018, , 1-60.		1
503	Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2021, 55, 239-243.	1.1	10
504	Bowel elastography â€“ a pilot study for developing an elastographic scoring system to evaluate disease activity in pediatric Crohn's disease.. Medical Ultrasonography, 2015, 17, 422-30.	0.4	24
505	Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms. Medical Science Monitor, 2016, 22, 4794-4802.	0.5	9
506	Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Research, 2020, 9, 54.	0.8	59
507	The Analysis of Factors Associated with Progression of Isolated Terminal Ileal Lesions. PLoS ONE, 2014, 9, e90797.	1.1	6
508	Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease. PLoS ONE, 2017, 12, e0185855.	1.1	40
509	A Practical Marker to Determining Acute Severe Ulcerative Colitis: CRP / Albumin Ratio. Ä°stanbul Kuzey Klinikleri, 2018, 7, 49-55.	0.1	15

#	ARTICLE	IF	CITATIONS
510	Metalloproteinase-3 and -9 as Novel Markers in the Evaluation of Ulcerative Colitis Activity in Children. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 103-110.	0.6	35
511	Can we rely on inflammatory biomarkers for the diagnosis and monitoring Crohn's disease activity?. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 828-833.	0.1	7
512	Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease. <i>Polish Archives of Internal Medicine</i> , 2008, 118, 622-626.	0.3	6
513	Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. <i>Caspian Journal of Internal Medicine</i> , 2017, 8, 178-182.	0.1	21
514	Role of Fecal Calprotectin as a Noninvasive Indicator for Ulcerative Colitis Disease Activity. <i>Folia Medica</i> , 2019, 61, 188-196.	0.2	3
515	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- α) inhibitors [LISA-TRACKER [®] enzyme-linked immunosorbent assay (ELISA) kits, TNF- α -Blocker ELISA kits and Promonitor [®] ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. <i>Health Technology Assessment</i> , 2016, 20, 1-288.	1.3	27
516	Fecal Calprotectin as a Useful Non-Invasive Screening Marker for Eosinophilic Gastrointestinal Disorder in Korean Children. <i>Journal of Korean Medical Science</i> , 2020, 35, e120.	1.1	12
517	C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 85.	1.4	46
518	Chronic pancreatitis: Maldigestion, intestinal ecology and intestinal inflammation. <i>World Journal of Gastroenterology</i> , 2009, 15, 1673.	1.4	40
519	Non-invasive investigation in patients with inflammatory joint disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2463.	1.4	6
520	Can chronic gastritis cause an increase in fecal calprotectin concentrations?. <i>World Journal of Gastroenterology</i> , 2010, 16, 3406.	1.4	19
521	Soluble ST2: A new and promising activity marker in ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2011, 17, 2181.	1.4	51
522	Utility of faecal calprotectin analysis in adult inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 6782.	1.4	56
523	Clinical significance of serum procalcitonin in patients with ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2013, 19, 8335.	1.4	22
524	Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 10916.	1.4	28
525	Clinical utility of a new endoscopic scoring system for Crohn's disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 9974.	1.4	6
526	Disease monitoring in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11246.	1.4	134
527	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. <i>World Journal of Gastroenterology</i> , 2017, 23, 3890.	1.4	28

#	ARTICLE	IF	CITATIONS
528	Albumin as a prognostic marker for ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 8008-8016.	1.4	50
529	Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. <i>World Journal of Gastroenterology</i> , 2017, 23, 8235-8247.	1.4	32
530	Layered enhancement at magnetic resonance enterography in inflammatory bowel disease: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4555-4566.	1.4	8
531	Chapter 9: Intestinal health biomarkers in vivo. , 2015, , 219-228.		2
532	Faecal Calgranulin C Versus Faecal Calprotectin as Non Invasive Markers Distinguishing Functional From Organic Causes of Chronic Diarrhea. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , 2014, 14, 179-191.	0.0	3
534	Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 360.	0.5	9
535	Diagnostic value of calprotectin in differentiation between benign and malignant pleural effusion. <i>Egyptian Journal of Bronchology</i> , 2019, 13, 382-387.	0.3	1
536	Role of Fecal Calprotectin in Monitoring Response to Therapy in Inflammatory Bowel Diseases. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	3
537	Domino effect of hypomagnesemia on the innate immunity of Crohn's disease patients. <i>World Journal of Diabetes</i> , 2014, 5, 527.	1.3	14
538	Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. <i>World Journal of Gastrointestinal Endoscopy</i> , 2020, 12, 504-520.	0.4	21
539	Markers of bacterial translocation in end-stage liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 2264.	0.8	45
540	Plasma transforming growth factor- γ 1 level in inflammatory bowel disease. <i>Turkish Journal of Gastroenterology</i> , 2009, 20, 165-170.	0.4	13
541	Red Cell Distribution Width: A Novel Marker of Activity in Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2011, 5, 460-467.	1.4	101
542	Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn's Disease: Results from the CONNECT Study. <i>Gut and Liver</i> , 2016, 10, 595-603.	1.4	14
543	A rapid test for assessing disease activity in ulcerative colitis. <i>Turkish Journal of Gastroenterology</i> , 2020, 27, 149-155.	0.4	7
544	Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease. <i>Intestinal Research</i> , 2017, 15, 311.	1.0	25
545	Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. <i>Intestinal Research</i> , 2018, 16, 546-553.	1.0	21
546	Fecal Myeloperoxidase as a Biomarker for Inflammatory Bowel Disease. <i>Cureus</i> , 2017, 9, e1004.	0.2	64

#	ARTICLE	IF	CITATIONS
547	Association between disease activity and ischaemia-modified albumin in patients with ulcerative colitis. <i>Przegląd Gastroenterologiczny</i> , 0, , .	0.3	0
548	Can we predict mucosal remission in ulcerative colitis more precisely with a redefined cutoff level of C-reactive protein?. <i>Colorectal Disease</i> , 2022, 24, 77-84.	0.7	3
549	Machine Learning Prediction Model for Inflammatory Bowel Disease Based on Laboratory Markers. Working Model in a Discovery Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4745.	1.0	13
550	Application of the neutrophil to lymphocyte ratio in the diagnosis and activity determination of ulcerative colitis. <i>Medicine (United States)</i> , 2021, 100, e27551.	0.4	6
551	Association of Fecal Calprotectin With Endoscopic and Histologic Activity in Pediatric Inflammatory Bowel Disease. <i>JPGN Reports</i> , 2021, 2, e129.	0.2	2
552	Preclinical Markers in Inflammatory Bowel Disease. A Nested Caseâ€“Control Study. <i>Crohn's & Colitis</i> 360, 2021, 3, .	0.5	2
553	Peripheral blood neutrophil-to-lymphocyte ratio in inflammatory bowel disease and disease activity: A meta-analysis. <i>International Immunopharmacology</i> , 2021, 101, 108235.	1.7	21
554	Ulcerative Colitis: Definition and General Description. , 2010, , 378-380.		0
555	Serological Markers in Inflammatory Bowel Disease. , 2011, , 9-20.		0
556	NHG-Standaard Rectaal bloedverlies. , 2011, , 151-177.		1
557	40 Rectaal bloedverlies. , 2011, , 521-536.		0
558	Inflammatory Bowel Disease in Pediatric Age. <i>Korean Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 14, S34.	0.2	3
559	Fecal Calprotectin Concentration and Clinical Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: Results from PRECISE 1. <i>American Journal of Gastroenterology</i> , 2011, 106, S441.	0.2	0
560	Fecal Calprotectin Concentration and Clinical Response to Certolizumab Pegol in Patients with Active Crohn's Disease: Results from PRECISE 2. <i>American Journal of Gastroenterology</i> , 2011, 106, S453.	0.2	1
562	Clinical, Biological, and Laboratory Parameters as Predictors of Severity of Clinical Outcome and Response to Antiâ€“TNFâ€“Alpha Treatment in Ulcerative Colitis. , 0, , .		0
563	Stuhlanalytik. , 2012, , 161-165.		0
564	Research of Immunology Markers of UC. , 0, , .		0
565	Faecal Calprotectin as Reliable Non-invasive Marker to Assess the Severity of Mucosal Inflammation in Patients with Ulcerative Colitis. <i>Afro-Egyptian Journal of Infectious and Endemic Diseases</i> , 2012, 2, 162-167.	0.1	0

#	ARTICLE	IF	CITATIONS
566	Molecular Profiling of IBD Subtypes/Response to Therapy. , 2013, , 151-169.		0
567	Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease. Polish Archives of Internal Medicine, 2013, 124, 51-57.	0.3	5
568	The Effect of Gender, Age and BMI on Postoperative C-Reactive Protein Levels After Major Abdominal Surgery. Journal of Current Surgery, 2014, , .	0.1	0
569	Fecal Calprotectin and Transforming Growth Factor-b1 in the Evaluation of Disease Activity in Patients with Ulcerative Colitis. Clinical Medicine Research, 2014, 3, 96.	0.0	0
570	Rectaal bloedverlies. Kernboek, 2016, , 633-653.	0.0	0
571	Measurement of Fractional Exhaled Nitric Oxide as a Marker of Disease Activity in Inflammatory Bowel Disease. Journal of Gastroenterology, Pancreatology & Liver Disorders, 2016, 3, 01-07.	0.2	7
572	Utility of fecal calprotectin as a discriminative biomarker between ulcerative colitis and irritable bowel syndrome and its ability to be used for the assessment of the remission stage of ulcerative colitis. The Egyptian Journal of Internal Medicine, 2016, 28, 21-27.	0.3	1
573	Laboratory Evaluation of Inflammatory Bowel Disease. , 2017, , 211-224.		0
574	Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, EC07-EC11.	0.8	1
575	Urin- und Stuhluntersuchungen. , 2017, , 185-196.		0
576	Prevalence of Adherent-Invasive Escherichia coli with fimH Gene Isolated from Iranian Patients with Ulcerative Colitis. Jundishapur Journal of Microbiology, 2017, 10, .	0.2	2
577	Crohn's disease activity evaluation based on imaging studies and biomarkers. Gastroenterology & Hepatology (Bartlesville, Okla), 2018, 9, .	0.0	0
578	The IBD outpatient care in the clinical practice. Vnitri Lekarstvi, 2018, 64, 654-658.	0.1	1
579	Optimal Usage of Fecal Calprotectin for Intestinal Diseases. Korean Journal of Medicine, 2018, 93, 364-368.	0.1	0
580	The importance of calprotectin for differentiating organic inflammatory disease and avoiding unnecessary procedures in paediatrics. Medicina Clínica (English Edition), 2018, 151, 231-235.	0.1	0
583	What Is the Utility of ESR and CRP in the Evaluation of Acute IBD Presentations?. , 2019, , 315-316.		0
584	Preoperative Neutrophil-to-Lymphocyte Ratio Is Correlated with Severe Postoperative Complications After Emergency Surgery for Ulcerative Colitis. International Surgery, 2019, 104, 514-521.	0.0	0
585	Recent advances in understanding and managing pediatric inflammatory bowel disease. F1000Research, 2019, 8, 2097.	0.8	4

#	ARTICLE	IF	CITATIONS
586	Is Mean Platelet Volume a Useful Noninvasive Biomarker for Inflammatory Bowel Disease in Childhood?. <i>The Journal of Medical Sciences</i> , 2021, 6, 4-7.	0.0	0
587	Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease. <i>Folia Medica</i> , 2020, 62, 271-275.	0.2	0
588	Correlation between Clinical Symptoms and Lab Tests with Endoscopic Severity Indexes in Patients with Inflammatory Bowel Diseases. <i>Middle East Journal of Digestive Diseases</i> , 2020, 12, 162-170.	0.2	1
589	The value of adenosine deaminase level in assessing activation of inflammatory bowel disease. <i>Journal of Surgery and Medicine</i> , 2020, 4, 654-659.	0.0	1
590	Age-Related Fecal Calprotectin Concentrations in Healthy Adults. <i>Korean Journal of Clinical Laboratory Science</i> , 2020, 52, 181-187.	0.1	5
591	Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What's New?. <i>Gastroenterology Insights</i> , 2020, 11, 58-71.	0.7	1
592	Proteases are cut out to regulate acute and chronic inflammation. , 2022, , 93-112.		1
593	PROGNOSTIC VALUE OF ULTRASOUND ACTIVITY AND PARIETAL HEALING IN PATIENTS WITH CROHN'S DISEASE.. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 113, 494-499.	0.1	1
594	Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097944.	1.4	4
595	Can red blood cell distribution width (RDW) predict clinical and endoscopic activity in ulcerative colitis patients?. <i>Journal of Surgery and Medicine</i> , 0, , .	0.0	1
596	The relationship between hematological parameters and disease activity in İnflammatory bowel disease. <i>Anadolu GÄ¼ncel TÄ±p Dergisi</i> , 0, , .	0.0	1
598	Reoperation for Inflammatory Bowel Disease. , 2008, , 257-277.		0
599	Äelseratif kolitte hastalÄ±n Äiddetini ÄngÄ±rmede non-invaziv belirteÄ±ler olarak hematolojik parametrelerin deÄerlendirilmesi. <i>Journal of Medicine and Palliative Care</i> ;, 2020, 1, 53-57.	0.0	1
600	Limitations in assessment of mucosal healing in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2010, 16, 15-20.	1.4	11
601	Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 917-25.	0.5	9
602	Probiotic yogurt Affects Pro- and Anti-inflammatory Factors in Patients with Inflammatory Bowel Disease. <i>Iranian Journal of Pharmaceutical Research</i> , 2013, 12, 929-36.	0.3	52
603	Update on current applications of proteomic in the study of inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2012, 25, 303-308.	0.4	2
604	A new model for the discrimination between ulcerative colitis and Crohn's disease. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 854-61.	1.3	0

#	ARTICLE	IF	CITATIONS
605	Correlation between triggering receptor expressed on myeloid cells-1 and clinical disease activity in Chinese patients with ulcerative colitis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 2147-55.	1.3	1
606	Can red cell distribution width be a marker of disease activity in ulcerative colitis?. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 13848-53.	1.3	4
607	Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 12319-32.	0.5	17
608	Fecal calprotectin Level in patients with IBD and noninflammatory disease of colon: a study in Babol, Northern, Iran. <i>Caspian Journal of Internal Medicine</i> , 2018, 9, 60-64.	0.1	3
609	Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings. <i>Nagoya Journal of Medical Science</i> , 2018, 80, 257-266.	0.6	3
610	IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4537-4544.	0.5	2
611	Upregulation of the transient receptor potential vanilloid 1 in colonic epithelium of patients with active inflammatory bowel disease. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 11335-11344.	0.5	4
612	IBD Diagnosis and Evaluation. , 2022, , 751-764.		0
613	Small-Bowel Capsule Endoscopy"Optimizing Capsule Endoscopy in Clinical Practice. <i>Diagnostics</i> , 2021, 11, 2139.	1.3	2
614	Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 513-524.	0.6	4
615	Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT"TOPIC trial after 1"year follow"up. <i>United European Gastroenterology Journal</i> , 2022, 10, 160-168.	1.6	16
616	Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1089-1096.	0.6	14
617	Can Fecal Calprotectin Reflect Your Colonic Status?. <i>Journal of Coloproctology</i> , 0, 42, .	0.1	0
618	Infrared spectrometric biomarkers for ulcerative colitis screening using human serum samples. <i>Journal of Biophotonics</i> , 2022, 15, e202100307.	1.1	4
620	Amino acids in inflammatory bowel diseases: Modern diagnostic tools and methodologies. <i>Advances in Clinical Chemistry</i> , 2022, 107, 139-213.	1.8	1
622	Relevance of Biotin Deficiency in Patients with Inflammatory Bowel Disease and Utility of Serum 3 Hydroxyisovaleryl Carnitine as a Practical Everyday Marker. <i>Journal of Clinical Medicine</i> , 2022, 11, 1118.	1.0	9
623	Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn"™s Disease. <i>Frontiers in Immunology</i> , 2022, 13, 865968.	2.2	4
624	Serum Albumin to Globulin Ratio is Associated with the Presence and Severity of Inflammatory Bowel Disease. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1907-1920.	1.6	8

#	ARTICLE	IF	CITATIONS
625	Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. <i>Frontiers in Public Health</i> , 2022, 10, 851295.	1.3	10
626	Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 613-621.	0.8	3
628	The albumin to globulin ratio is associated with clinical outcome in Japanese patients with ulcerative colitis. <i>Annals of Coloproctology</i> , 2023, 39, 155-163.	0.5	3
629	Paediatric Crohn's Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. <i>GastroHep</i> , 2022, 2022, 1-11.	0.3	0
630	Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 51-61.	0.9	5
631	Toll-Like Receptors/TNF- α Pathway Crosstalk and Impact on Different Sites of Recurrent Myocardial Infarction in Elderly Patients. <i>BioMed Research International</i> , 2022, 2022, 1-11.	0.9	4
632	Sprayable nanomicelle hydrogels and inflammatory bowel disease patient cell chips for development of intestinal lesion-specific therapy. <i>Bioactive Materials</i> , 2022, 18, 433-445.	8.6	8
633	Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. <i>Life</i> , 2021, 11, 1375.	1.1	15
646	Delayed Infliximab Treatment Affects the Outcomes of Patients With Crohn's Disease During the COVID-19 Epidemic in China: A Propensity Score-Matched Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 819557.	1.2	2
649	Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2479.	1.0	2
650	Gut Dysbiosis Is Associated With the Severity of Cryptogenic Stroke and Enhanced Systemic Inflammatory Response. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	8
651	Epidemiological characteristics of Asian children with inflammatory bowel disease at diagnosis: Insights from an Asian-Pacific multi-centre registry network. <i>World Journal of Gastroenterology</i> , 2022, 28, 1830-1844.	1.4	8
652	Neutrophil-to-Lymphocyte Ratio: An Easy Marker for the Diagnosis and Monitoring of Inflammatory Bowel Disease in Children. <i>Digestive Diseases and Sciences</i> , 2022, , .	1.1	5
653	Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human. <i>AAPS PharmSciTech</i> , 2022, 23, 148.	1.5	2
654	Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 257, 301-308.	0.5	6
655	The Impact of Intestinal Ultrasound on the Management of Inflammatory Bowel Disease: From Established Facts Toward New Horizons. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	5
656	Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
657	Polyphenols and Ulcerative Colitis: An Exploratory Study of the Effects of Red Wine Consumption on Gut and Oral Microbiome in Active-Phase Patients. <i>Molecular Nutrition and Food Research</i> , 2022, 66, .	1.5	7

#	ARTICLE	IF	CITATIONS
658	Antibody signatures in inflammatory bowel disease: current developments and future applications. Trends in Molecular Medicine, 2022, 28, 693-705.	3.5	8
660	Alterations in Blood Plasma Metabolome of Patients with Lesniowski-Crohn's Disease Shortly after Surgical Treatment—Pilot Study. Metabolites, 2022, 12, 529.	1.3	0
661	The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease. Biomedicines, 2022, 10, 1492.	1.4	18
662	Severe, Recurrent Anemia in a 17-Year-Old Female. Clinical Pediatrics, 0, , 000992282211017.	0.4	0
663	Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Review of Gastroenterology and Hepatology, 2022, 16, 721-735.	1.4	6
664	C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. Revista De GastroenterologĂa De MĂxico (English Edition), 2022, 87, 447-454.	0.1	2
665	(Re)Appraising Remission in Ulcerative Colitis. Inflammatory Bowel Diseases, 0, , .	0.9	0
666	Signs and Symptoms of Acute Bowel Inflammation and the Risk of Progression to Inflammatory Bowel Disease: A Retrospective Analysis. Journal of Clinical Medicine, 2022, 11, 4595.	1.0	1
667	Bionic Regulators Break the Ecological Niche of Pathogenic Bacteria for Modulating Dysregulated Microbiome in Colitis. Advanced Materials, 2022, 34, .	11.1	20
668	Mannose ameliorates experimental colitis by protecting intestinal barrier integrity. Nature Communications, 2022, 13, .	5.8	55
669	Analysis of biomarkers and composite scores in IBD patients using probabilistic fuzzy systems. , 2022, , .		0
670	Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study. Cancers, 2022, 14, 4213.	1.7	3
671	Plasma proteome responses in zebrafish following Î»-carrageenan-Induced inflammation are mediated by PMN leukocytes and correlate highly with their human counterparts. Frontiers in Immunology, 0, 13, .	2.2	14
672	Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study. BMC Gastroenterology, 2022, 22, .	0.8	0
673	Application of the Clustering Technique to Multiple Nutritional Factors Related to Inflammation and Disease Progression in Patients with Inflammatory Bowel Disease. Nutrients, 2022, 14, 3960.	1.7	3
674	Inflammatory markers in clinical practice. Vnitřni Lekarstvi, 2022, 68, E11-E16.	0.1	1
675	C-reactive protein values after surgery for inflammatory bowel disease: is it still a good marker for intra-abdominal complication? A retrospective cohort study of 347 procedures. International Journal of Colorectal Disease, 0, , .	1.0	1
676	Integrating Radiomics With Clinicoradiological Scoring Can Predict High-Risk Patients Who Need Surgery in Crohn's Disease: A Pilot Study. Inflammatory Bowel Diseases, 2023, 29, 349-358.	0.9	7

#	ARTICLE	IF	CITATIONS
677	NONINVASIVE DIAGNOSIS OF COLORECTAL CANCER AND ULCERATIVE COLITIS BASED ON THE COMBINED USE OF FECAL LACTOFERRIN AND IMMUNOCHEMICAL HEMOCCULT TEST. <i>Problemy Zdorov'ya I Ākologii</i> , 2011, 0.0, 142-146.		0
678	ALGORITHM FOR DIFFERENTIAL DIAGNOSIS OF THE MOST PREVALENT ORGANIC AND FUNCTIONAL BOWEL PATHOLOGY. <i>Problemy Zdorov'ya I Ākologii</i> , 2012, , 76-79.	0.0	0
679	The Correlation between New Serological Markers and Disease Phenotype and Activation in Inflammatory Bowel Disease. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 294-303.	0.2	2
680	The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	0
681	Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 475-485.	1.9	9
682	Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. <i>Digestion</i> , 2023, 104, 30-41.	1.2	20
683	Gut microbiota analysis for prediction of clinical relapse in Crohn's disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
684	Common laboratory blood test immune panel markers are useful for grading ulcerative colitis endoscopic severity. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	4
685	Labordiagnostik. , 2023, , 79-86.		0
686	Biomarkers of Intestinal Injury in Colic. <i>Animals</i> , 2023, 13, 227.	1.0	3
687	Amino acids-targeted metabolomics reveals novel diagnostic biomarkers for ulcerative colitis and Crohn's disease. <i>Amino Acids</i> , 2023, 55, 349-358.	1.2	5
688	Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1 α and NRF2 as therapeutic targets. <i>Redox Biology</i> , 2023, 60, 102603.	3.9	26
689	Synbiotic-IgY Therapy Modulates the Mucosal Microbiome and Inflammatory Indices in Dogs with Chronic Inflammatory Enteropathy: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Veterinary Sciences</i> , 2023, 10, 25.	0.6	5
691	A magnetic resonance enterography index for assessing small bowel Crohn's disease activity. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, .	1.1	0
692	PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2023, 76, 451-459.	0.9	1
693	Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 307-320.	3.7	42
694	Evaluation of Crohn's Disease Small-Bowel Mucosal Healing Using Capsule Endoscopy and Usefulness of Leucine-Rich α 2-Glycoprotein. <i>Diagnostics</i> , 2023, 13, 626.	1.3	0
695	MIF Variant rs755622 Is Associated with Severe Crohn's Disease and Better Response to Anti-TNF Adalimumab Therapy. <i>Genes</i> , 2023, 14, 452.	1.0	2

#	ARTICLE	IF	CITATIONS
696	Ion Mobility Spectrometry for the Metabolomic Study of Inflammatory Bowel Disease Using the Volatile Organic Compounds Profile in Human Serum and Urine. <i>Chemosensors</i> , 2023, 11, 139.	1.8	1
697	Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort. <i>United European Gastroenterology Journal</i> , 2023, 11, 179-188.	1.6	7
698	Laboratory Evaluation of Inflammatory Bowel Disease. , 2023, , 229-244.		0
699	Clinical and laboratory markers of the pre-test probability of inflammatory bowel diseases. <i>Koloproktologia</i> , 2023, 22, 91-98.	0.1	1
700	Efficacy of <i>Bifidobacterium longum</i> alone or in multi-strain probiotic formulations during early life and beyond. <i>Gut Microbes</i> , 2023, 15, .	4.3	7
701	Evaluation of plasma soluble urokinase plasminogen activator receptor (SuPAR) levels in ulcerative colitis. <i>Arab Journal of Gastroenterology</i> , 2023, , .	0.4	0